Comparing Bayesian early stopping boundaries for phase II clinical trials

2020 ◽  
Vol 19 (6) ◽  
pp. 928-939
Author(s):  
Liyun Jiang ◽  
Fangrong Yan ◽  
Peter F. Thall ◽  
Xuelin Huang
Keyword(s):  
Clinical Trials ◽  
Phase Ii ◽  
Early Stopping ◽  
Phase Ii Clinical Trials

Naphthoquinone Derivatives Isolated from Plants: Recent Advances in Biological Activity

2020 ◽  
Vol 20 (19) ◽  
pp. 2019-2035
Author(s):  
Esmaeil Sheikh Ahmadi ◽  
Amir Tajbakhsh ◽  
Milad Iranshahy ◽  
Javad Asili ◽  
Nadine Kretschmer ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Biological Activity ◽  
Small Molecules ◽  
Anticancer Activity ◽  
Clinical Significance ◽  
Phase Ii ◽  
Biological Activities ◽  
Phase Ii Clinical Trials ◽  
Naturally Occurring ◽  
The Subject

Naturally occurring naphthoquinones (NQs) comprising highly reactive small molecules are the subject of increasing attention due to their promising biological activities such as antioxidant, antimicrobial, apoptosis-inducing activities, and especially anticancer activity. Lapachol, lapachone, and napabucasin belong to the NQs and are in phase II clinical trials for the treatment of many cancers. This review aims to provide a comprehensive and updated overview on the biological activities of several new NQs isolated from different species of plants reported from January 2013 to January 2020, their potential therapeutic applications and their clinical significance.

Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials

2009 ◽  
Vol 52 (4) ◽  
pp. 283-288 ◽  
Author(s):  
R. Barbouche ◽  
E. Fenouillet ◽  
M.-J. Papandréou ◽  
M.P. Kiény ◽  
J M. Sabatier
Keyword(s):  
Clinical Trials ◽  
Phase Ii ◽  
Peptide Drug ◽  
Phase Ii Clinical Trials ◽  
Hiv Envelope
Sign in / Sign up

Export Citation Format

Share Document